| Literature DB >> 32553167 |
Brock G Bennion1, Carys A Croft2, Teresa L Ai3, Wei Qian3, Amber M Menos3, Cathrine A Miner3, Marie-Louis Frémond4, Jean-Marc Doisne5, Prabhakar S Andhey1, Derek J Platt6, Jennifer K Bando1, Erin R Wang3, Hella Luksch7, Thierry J Molina8, Elisha D O Roberson9, Maxim N Artyomov1, Angela Rösen-Wolff7, Marco Colonna1, Frédéric Rieux-Laucat10, James P Di Santo5, Bénédicte Neven11, Jonathan J Miner12.
Abstract
STING gain-of-function causes autoimmunity and immunodeficiency in mice and STING-associated vasculopathy with onset in infancy (SAVI) in humans. Here, we report that STING gain-of-function in mice prevents development of lymph nodes and Peyer's patches. We show that the absence of secondary lymphoid organs is associated with diminished numbers of innate lymphoid cells (ILCs), including lymphoid tissue inducer (LTi) cells. Although wild-type (WT) α4β7+ progenitors differentiate efficiently into LTi cells, STING gain-of-function progenitors do not. Furthermore, STING gain-of-function impairs development of all types of ILCs. Patients with STING gain-of-function mutations have fewer ILCs, although they still have lymph nodes. In mice, expression of the STING mutant in RORγT-positive lineages prevents development of lymph nodes and reduces numbers of LTi cells. RORγT lineage-specific expression of STING gain-of-function also causes lung disease. Since RORγT is expressed exclusively in LTi cells during fetal development, our findings suggest that STING gain-of-function prevents lymph node organogenesis by reducing LTi cell numbers in mice.Entities:
Keywords: ILC; LTi cell; Peyer's patch; SAVI; STING; STING-associated vasculopathy with onset in infancy; innate lymphoid cell; lymph node; lymphoid tissue organogenesis; lymphopoiesis
Mesh:
Year: 2020 PMID: 32553167 PMCID: PMC7372600 DOI: 10.1016/j.celrep.2020.107771
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423